Psyence Biomedical Ltd. (PBM) Achieves Breakthrough in High-Purity Ibogaine Production

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Psyence Biomedical Ltd. is one of them.

Psyence Biomedical Ltd. (NASDAQ:PBM) is a biopharmaceutical company developing naturally derived psychedelic medicines, including psilocybin and ibogaine, targeting serious mental health conditions in palliative care and other complex disorders. It stands thirteenth on our list among the best psychedelic stocks. The company has recently made notable strides in both clinical progress and strategic positioning.

In August 2025, Psyence Biomedical Ltd. (NASDAQ:PBM) BioMed expanded patient eligibility for its clinical trials by removing the requirement that cancer patients be terminally diagnosed, significantly broadening the potential patient pool. Three clinical trial sites have been activated, and patient enrollment is expected to accelerate, supported by a Scientific Advisory Board of leading experts in neuroscience and psychedelic medicine.

The business also achieved a breakthrough in psychedelic drug production through its collaboration with PsyLabs, producing a high-purity ibogaine total alkaloid extract that meets global pharmaceutical standards. This milestone strengthens the corporation’s ability to supply active pharmaceutical ingredients for clinical research and therapeutic applications and has contributed to positive investor sentiment.

Financially, Psyence Biomedical Ltd. (NASDAQ:PBM) has stabilized, with over $11 million in cash and no debt, following a reverse stock split earlier in 2025 to regain Nasdaq compliance. Its unique operational presence in Africa, combined with regulatory and clinical advancements, provides a competitive edge in the emerging psychedelic medicine sector.

Looking ahead, the company will present at the H.C. Wainwright 27th Annual Global Investment Conference in September 2025, highlighting its clinical pipeline and business strategy.

While we acknowledge the potential of PBM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.